Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IMP4297 + irinotecan
- Development stage
- Unknown
- Lead developer
- IMPACT Therapeutics
- Modality
- Small Molecules
- Administration
- Oral (senaparib), Intravenous (irinotecan)
01
Overview
IMP4297 + irinotecan is a combination of **senaparib (IMP4297)**, a small molecule poly(ADP-ribose) polymerase (PARP) inhibitor, and **irinotecan**, a topoisomerase I inhibitor. Senaparib selectively inhibits PARP enzymes, leading to accumulation of DNA damage and synthetic lethality particularly in tumor cells deficient in homologous recombination repair. Irinotecan inhibits topoisomerase I, causing DNA damage during replication. The combination is being investigated for synergistic anti-tumor effects in advanced malignant solid tumors, including small cell lung cancer, by disrupting two distinct but complementary DNA repair and damage response pathways. Senaparib is developed primarily by IMPACT Therapeutics.
- Brand names
- Paishuning
- Other names
- senaparib + irinotecanIMP4297 + irinotecan
02
Targets
TOP1 (DNA Topoisomerase I)PARP2 (Poly (adp-ribose) polymerase 2)
Beyond the preview
Go deeper on IMP4297 + irinotecan.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IMP4297 + irinotecan.